Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.03 by 266.67 percent. This is a 184.62 percent increase over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $129.861 million which beat the analyst consensus estimate of $118.852 million by 9.26 percent. This is a 59.33 percent increase over sales of $81.504 million the same period last year.